Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
3.
Australas J Dermatol ; 63(2): e145-e149, 2022 May.
Article in English | MEDLINE | ID: mdl-35429339

ABSTRACT

A 25-year-old male patient presented with palmoplantar keratoderma, dystrophic nails, severe plantar pain and oral leukokeratosis since birth. On genetic analysis, a heterozygous KRT6A gene missense mutation (c.1381G > A, p.Glu461Lys in exon 7) was identified by next-generation sequencing technology, consistent with pachyonychia congenita 6a. Oral simvastatin 40 mg was started once daily, and after 16 weeks of therapy, excellent improvement was noted in palmoplantar keratoderma and plantar pain. The maximum thickness of his foot callosity reduced by 4 mm on ultrasonography, and the Dermatology Life Quality Index score dropped significantly by eight points. These benefits may be attributed to inhibition of KRT6A gene expression, modulation of autophagy and mitophagy and Keap1-Nrf2 signalling activation; the latter two mechanisms of statins previously undiscussed in the context of pachyonychia congenita. Simvastatin and other statins are pathogenesis-targeted, disease-modifying therapy in pachyonychia congenita, therefore qualifying as a promising treatment avenue and warranting further clinical trials.


Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors , Keratoderma, Palmoplantar , Pachyonychia Congenita , Adult , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Kelch-Like ECH-Associated Protein 1/genetics , Keratin-6/genetics , Keratoderma, Palmoplantar/genetics , Male , Mutation , NF-E2-Related Factor 2/genetics , NF-E2-Related Factor 2/therapeutic use , Pachyonychia Congenita/drug therapy , Pachyonychia Congenita/genetics , Pain , Simvastatin/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...